Skip to main content
Patient portrayal of a woman

Prescribed SCEMBLIX? You may be able to save from the start

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.
To learn more, call 1-800-282-7630 or visit

Icon of calendar

New to SCEMBLIX? Get a voucher for up to a free 30-day supply

If you have been prescribed SCEMBLIX, you may be eligible to receive up to a free 30-day supply, which will allow you to start your prescribed treatment quickly. Program rules may vary.

Image of the OpusHealth 30-day free supply voucher
Icon of dollar sign

Co-pays as low as $0*

You may be eligible for immediate co-pay savings on your next prescription of SCEMBLIX.

  • Eligible patients with private insurance may pay $0 per month
  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product* 

To find out if you are eligible for the Novartis Oncology Universal Co-pay Program, call 1-877-577-7756 or visit

The Novartis Universal Co-pay Card: You may be eligible for immediate co-pay savings on your next prescription of SCEMBLIX.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit
or call 1-877-577-7756.

Important Safety Information

Before taking SCEMBLIX, tell your doctor about all your medical conditions, including if you:

  • have a history of inflammation of your pancreas (pancreatitis)
  • have a history of heart problems or blood clots in your arteries and veins (types of blood vessels)
  • are pregnant or plan to become pregnant. SCEMBLIX can harm your unborn baby ...

Approved Uses

SCEMBLIX is a prescription medicine used to treat adults with:

  • Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
  • Ph+ CML in CP with the T315I mutation ...